- Home
- SCYX vs BODI Comparison
SCYX vs BODI Comparison
Compare SCYX & BODI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- BODI
- Stock Information
- Founded
- SCYX 1999
- BODI 1998
- Country
- SCYX United States
- BODI United States
- Employees
- SCYX N/A
- BODI N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- BODI Industrial Machinery/Components
- Sector
- SCYX Health Care
- BODI Industrials
- Exchange
- SCYX Nasdaq
- BODI Nasdaq
- Market Cap
- SCYX 34.9M
- BODI 40.1M
- IPO Year
- SCYX 2014
- BODI N/A
- Fundamental
- Price
- SCYX $1.10
- BODI $6.74
- Analyst Decision
- SCYX
- BODI Buy
- Analyst Count
- SCYX 0
- BODI 2
- Target Price
- SCYX N/A
- BODI $10.00
- AVG Volume (30 Days)
- SCYX 204.1K
- BODI 14.9K
- Earning Date
- SCYX 11-05-2025
- BODI 11-11-2025
- Dividend Yield
- SCYX N/A
- BODI N/A
- EPS Growth
- SCYX N/A
- BODI N/A
- EPS
- SCYX N/A
- BODI N/A
- Revenue
- SCYX $3,257,000.00
- BODI $324,871,000.00
- Revenue This Year
- SCYX $422.61
- BODI N/A
- Revenue Next Year
- SCYX $240.56
- BODI N/A
- P/E Ratio
- SCYX N/A
- BODI N/A
- Revenue Growth
- SCYX N/A
- BODI N/A
- 52 Week Low
- SCYX $0.66
- BODI $3.38
- 52 Week High
- SCYX $1.66
- BODI $8.71
- Technical
- Relative Strength Index (RSI)
- SCYX 71.20
- BODI 75.51
- Support Level
- SCYX $0.81
- BODI $5.30
- Resistance Level
- SCYX $1.31
- BODI $6.42
- Average True Range (ATR)
- SCYX 0.07
- BODI 0.41
- MACD
- SCYX 0.03
- BODI 0.07
- Stochastic Oscillator
- SCYX 58.33
- BODI 92.57
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.